← Leaderboards
Nira Pollock
Beth Israel Deaconess Medical Center
$9,552,528
Attributed
$37,990,077
Total exposure
12
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.6M · FY2008–22$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$37,990,077 · 12
By mechanism
U19$30,000,379 · 6
R01$4,136,224 · 1
U01$1,705,157 · 1
R21$1,515,167 · 3
K23$633,150 · 1
Top collaborators
- Darrell P Chandler31 shared
- Aedin C Culhane31 shared
- Molly Forrest Franke31 shared
- Jerome Timothy Galea31 shared
- Anne Goldfeld31 shared
- Louise Catherine Ivers31 shared
- Ann Chesney Miller31 shared
- Eric Joseph Rubin31 shared
Others in their field
Top investigators on “Diagnosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$590,717,255
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$337,858,596
- Richard K. Wilson · Washington University$297,645,172
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Carol Nesel · Westat$188,148,170
Research focus
DiagnosisDiagnosticDiagnostic TestsInnovationBaseMycobacterium TuberculosisDetectionTechnologyDrug Resistance In TuberculosisChildDrug ResistanceUrineTuberculosisAdultChildhoodPeruSamplingEvaluationResourcesInfectionLeadPerformanceCommunicable DiseasesDesign
Grant awards (48)
A point-of-care device using Single Molecule Array (Simoa) to measure viral antigens in nasal swabs, saliva, and blood$1,705,157
U01 · FY2022 · EB
Ultrasensitive C.difficile toxin measurement for diagnosis and outcome prediction$823,989
R01 · FY2020 · AI · contact PI
Ultrasensitive C.difficile toxin measurement for diagnosis and outcome prediction$809,845
R01 · FY2019 · AI · contact PI
A paperfluidic molecular diagnostic for Trichomonas vaginalis$209,295
R21 · FY2019 · AI
Sequencing Core$2,595,356
U19 · FY2018 · AI
Genetic determinants of drug resistance in Mycobacteria tuberculosis$1,274,314
U19 · FY2018 · AI
Discovery and validation of drug resistance mutations$938,261
U19 · FY2018 · AI
Innovative Strategies to Improve Tuberculosis Diagnostics in Children$888,730
U19 · FY2018 · AI
Ultrasensitive C.difficile toxin measurement for diagnosis and outcome prediction$813,471
R01 · FY2018 · AI · contact PI
Administrative Core$412,046
U19 · FY2018 · AI
Integrated system for Category C infectious disease diagnostics in resource-limi$403,448
U19 · FY2018 · AI
A paperfluidic molecular diagnostic for Trichomonas vaginalis$266,774
R21 · FY2018 · AI
Integrated system for Category C infectious disease diagnostics in resource-limi$2,182,203
U19 · FY2017 · AI
Innovative Strategies to Improve Tuberculosis Diagnostics in Children$1,095,803
U19 · FY2017 · AI
Genetic determinants of drug resistance in Mycobacteria tuberculosis$913,253
U19 · FY2017 · AI
Ultrasensitive C.difficile toxin measurement for diagnosis and outcome prediction$832,443
R01 · FY2017 · AI · contact PI
Discovery and validation of drug resistance mutations$734,112
U19 · FY2017 · AI
Administrative Core$616,131
U19 · FY2017 · AI
Sequencing Core$408,777
U19 · FY2017 · AI
Integrated system for Category C infectious disease diagnostics in resource-limi$2,528,705
U19 · FY2016 · AI
Innovative Strategies to Improve Tuberculosis Diagnostics in Children$992,134
U19 · FY2016 · AI
Ultrasensitive C.difficile toxin measurement for diagnosis and outcome prediction$856,476
R01 · FY2016 · AI · contact PI
Discovery and validation of drug resistance mutations$750,894
U19 · FY2016 · AI
Genetic determinants of drug resistance in Mycobacteria tuberculosis$715,308
U19 · FY2016 · AI
Sequencing Core$421,675
U19 · FY2016 · AI
Administrative Core$410,524
U19 · FY2016 · AI
Borrelia antigen detection assay for urine-based diagnosis of early Lyme disease$233,063
R21 · FY2016 · AI · contact PI
Genetic determinants of drug resistance in Mycobacteria tuberculosis$82,633
U19 · FY2016 · AI
Integrated system for Category C infectious disease diagnostics in resource-limi$2,500,809
U19 · FY2015 · AI
Innovative Strategies to Improve Tuberculosis Diagnostics in Children$932,090
U19 · FY2015 · AI
Discovery and validation of drug resistance mutations$774,241
U19 · FY2015 · AI
Sequencing Core$660,525
U19 · FY2015 · AI
Genetic determinants of drug resistance in Mycobacteria tuberculosis$500,331
U19 · FY2015 · AI
Borrelia antigen detection assay for urine-based diagnosis of early Lyme disease$318,019
R21 · FY2015 · AI · contact PI
Administrative Core$311,434
U19 · FY2015 · AI
Integrated system for Category C infectious disease diagnostics in resource-limi$2,916,905
U19 · FY2014 · AI
Innovative Strategies to Improve Tuberculosis Diagnostics in Children$900,727
U19 · FY2014 · AI
Sequencing Core$822,385
U19 · FY2014 · AI
Discovery and validation of drug resistance mutations$554,926
U19 · FY2014 · AI
Genetic determinants of drug resistance in Mycobacteria tuberculosis$536,059
U19 · FY2014 · AI
Administrative Core$225,640
U19 · FY2014 · AI
Ultrasensitive quantitative digital ELISA for C. difficile toxins in stool$215,007
R21 · FY2014 · AI · contact PI
Ultrasensitive quantitative digital ELISA for C. difficile toxins in stool$273,009
R21 · FY2013 · AI · contact PI
Development and Evaluation of a Novel Diagnostic Test for Active Tuberculosis$126,630
K23 · FY2012 · AI · contact PI
Development and Evaluation of a Novel Diagnostic Test for Active Tuberculosis$126,630
K23 · FY2011 · AI · contact PI
Development and Evaluation of a Novel Diagnostic Test for Active Tuberculosis$126,630
K23 · FY2010 · AI · contact PI
Development and Evaluation of a Novel Diagnostic Test for Active Tuberculosis$126,630
K23 · FY2009 · AI · contact PI
Development and Evaluation of a Novel Diagnostic Test for Active Tuberculosis$126,630
K23 · FY2008 · AI · contact PI